We work with researchers, hospitals and leading biotech/pharma companies to explore and discover transformative drugs with the aim to cure patients.
Innovent Biologics has a strong track record in research and development of high-end biomedicines, clinical studies and product launch. IASO partnered with Innovent in the joint development of a BCMA-targeted CAR-T cell therapy.
The University of Pennsylvania is a renowned private research university and a member of the Ivy League. IASO collaborated with UPenn in the development of optimal processes for cell therapies.
Adimab is a global leader in discovery and optimization of fully-human monoclonal and bispecific antibodies. IASO partnered with Adimab in the development of several antibody series.
Tongji Hospital (TJH) is one of the leading hospitals specializing in cell therapies. IASO and TJH have jointly conducted IIT and registrational clinical studies on multiple cell therapies.
Multiple clinical studies are underway with over 10 top-tier national hospitals with broad patient access in the areas of oncology and autoimmune diseases, including hospitals affiliated with Zhejiang University School of Medicine, Tianjin Blood Institute, and the Henan Cancer Hospital
